[Drug lowering of the HDL concentration in the serum of cardiologically treated patients]
- PMID: 6129752
[Drug lowering of the HDL concentration in the serum of cardiologically treated patients]
Abstract
The connection between decreased concentration of HDL-cholesterol in the serum and increased risk of arteriosclerosis has attracted the attention to such sizes of influence which are able to decrease the HDL-cholesterol-concentration. In these cases the question is asked, whether the analytic reliability of the techniques which are at the disposal for the estimation of HDL-cholesterol is sufficient for the recognition of the changes of the concentration to be expected. To the sizes of influence belong medicaments which cannot be fancied away in the therapy of cardiovascular diseases; thus the beta-receptor blockers talinolol and propranolol. The examination of 118 cardiologically treated patients yields the result that there is no particular risk of the patients treated by means of these medicaments, since an essential decrease of the HDL-cholesterol-concentration could not be proved.
Similar articles
-
[Lipoprotein metabolism and beta receptor blockers].Z Gesamte Inn Med. 1987 Apr 15;42(8):201-5. Z Gesamte Inn Med. 1987. PMID: 2888241 German.
-
[Value of combination therapy of pentalong (PETN) with obsidan (propranolol) in patients with coronary insufficiency].Z Arztl Fortbild (Jena). 1977 Feb 15;71(4):167-71. Z Arztl Fortbild (Jena). 1977. PMID: 868090 German. No abstract available.
-
Concomitant use of policosanol and beta-blockers in older patients.Int J Clin Pharmacol Res. 2004;24(2-3):65-77. Int J Clin Pharmacol Res. 2004. PMID: 15689053 Clinical Trial.
-
The emerging problem of plasma lipid changes during antihypertensive therapy.J Cardiovasc Pharmacol. 1982;4 Suppl 2:S213-21. J Cardiovasc Pharmacol. 1982. PMID: 6177959 Review.
-
Serum lipoproteins during treatment with antihypertensive drugs.J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98-105. J Cardiovasc Pharmacol. 1993. PMID: 7508069 Review.